ATNF — 180 Life Sciences Share Price
0.000.00%
Last trade - 00:00- $5.92m
- $2.35m
- 12
- 45
- 25
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.73 | ||
| Price to Tang. Book | 4.12 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -84.8% | ||
| Return on Equity | -310.82% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 16.64 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
180 Life Sciences Corp. is a biotechnology company, which focuses on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. Its programs include Anti-TNF (Clinical), Synthetic Cannabinoid Analogs (SCAs), and a7nAChR (Preclinical). The Company also operates back-end technology platform to operate an online blockchain casino.
Directors
- Marc Feldmann CCH (76)
- Lawrence Steinman CCH (73)
- James Woody CEO (78)
- Ozan Pamir CFO (30)
- Quan Anh Vu COO
- Jonathan Rothbard CSO (69)
- Donald McGovern LED (70)
- Teresa DeLuca IND (55)
- Larry Gold IND (79)
- Francis Knuettel IND (55)
- Pamela Marrone IND (64)
- Russell Ray IND (73)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 7th, 2016
- Public Since
- June 7th, 2017
- No. of Shareholders
- 122
- No. of Employees
- 4
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 5,695,487
- Address
- 3000 El Camino Real, Bldg 4, Ste 200, PALO ALTO, 94306
- Web
- https://180lifesciences.com/
- Phone
- +1 6505070669
- Contact
- Jason Assad
- Auditors
- Marcum LLP
Upcoming Events for ATNF
Q3 2025 180 Life Sciences Corp Earnings Release
Similar to ATNF
36Kr Holdings
NASDAQ Capital Market
3 E Network Technology
NASDAQ Capital Market
A2Z Cust2mate Solutions
NASDAQ Capital Market
Abits
NASDAQ Capital Market
Aegis Identity Software
NASDAQ Capital Market
FAQ
What is the 180 Life Sciences share price?
As of Today at 19:00 UTC, shares in 180 Life Sciences are trading at $1.18. This share price information is delayed by 15 minutes.
How has the 180 Life Sciences share price performed this year?
Shares in 180 Life Sciences last closed at $1.18 and the price had moved by -28.48% over the past 365 days. In terms of relative price strength the 180 Life Sciences share price has underperformed the S&P500 Index by -36.35% over the past year.
What are the analyst and broker recommendations for 180 Life Sciences?
The overall consensus recommendation for 180 Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the 180 Life Sciences dividend yield?
180 Life Sciences does not currently pay a dividend.
Does 180 Life Sciences pay a dividend?
180 Life Sciences does not currently pay a dividend.
When does 180 Life Sciences next pay dividends?
180 Life Sciences does not currently pay a dividend.
How do I buy 180 Life Sciences shares?
To buy shares in 180 Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of 180 Life Sciences?
As of the previous close price of $1.18, shares in 180 Life Sciences had a market capitalisation of $6.72m.
Where are 180 Life Sciences shares listed?
Here are the trading details for 180 Life Sciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ATNF
What kind of share is 180 Life Sciences?
Based on an overall assessment of its quality, value and momentum 180 Life Sciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a 180 Life Sciences share price forecast for 2025?
The analyst consensus target price for shares in 180 Life Sciences is $80.00. That is 6679.66% above the last closing price of $1.18.
Analysts covering 180 Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the 180 Life Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 180 Life Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -53.31%.
As of the last closing price of $1.18, shares in 180 Life Sciences were trading -34.36% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the 180 Life Sciences PE Ratio?
The 180 Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of 180 Life Sciences?
180 Life Sciences' management team is headed by:
- Marc Feldmann - CCH
- Lawrence Steinman - CCH
- James Woody - CEO
- Ozan Pamir - CFO
- Quan Anh Vu - COO
- Jonathan Rothbard - CSO
- Donald McGovern - LED
- Teresa DeLuca - IND
- Larry Gold - IND
- Francis Knuettel - IND
- Pamela Marrone - IND
- Russell Ray - IND